Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 43

1.

Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.

Jensen SB, Fahnøe U, Pham LV, Serre SBN, Tang Q, Ghanem L, Pedersen MS, Ramirez S, Humes D, Pihl AF, Filskov J, Sølund CS, Dietz J, Fourati S, Pawlotsky JM, Sarrazin C, Weis N, Schønning K, Krarup H, Bukh J, Gottwein JM.

Hepatology. 2019 Sep;70(3):771-787. doi: 10.1002/hep.30647. Epub 2019 Jun 5.

2.

High density Huh7.5 cell hollow fiber bioreactor culture for high-yield production of hepatitis C virus and studies of antivirals.

Pihl AF, Offersgaard AF, Mathiesen CK, Prentoe J, Fahnøe U, Krarup H, Bukh J, Gottwein JM.

Sci Rep. 2018 Nov 30;8(1):17505. doi: 10.1038/s41598-018-35010-5.

3.

HCV genotype 1-6 NS3 residue 80 substitutions impact protease inhibitor activity and promote viral escape.

Pham LV, Jensen SB, Fahnøe U, Pedersen MS, Tang Q, Ghanem L, Ramirez S, Humes D, Serre SBN, Schønning K, Bukh J, Gottwein JM.

J Hepatol. 2019 Mar;70(3):388-397. doi: 10.1016/j.jhep.2018.10.031. Epub 2018 Nov 3.

PMID:
30395912
4.

Recombinant hepatitis C virus genotype 5a infectious cell culture systems expressing minimal JFH1 NS5B sequences permit polymerase inhibitor studies.

Humes D, Ramirez S, Jensen TB, Li YP, Gottwein JM, Bukh J.

Virology. 2018 Sep;522:177-192. doi: 10.1016/j.virol.2018.05.020. Epub 2018 Jul 20.

5.

Antiviral Effect of Ribavirin against HCV Associated with Increased Frequency of G-to-A and C-to-U Transitions in Infectious Cell Culture Model.

Galli A, Mens H, Gottwein JM, Gerstoft J, Bukh J.

Sci Rep. 2018 Mar 15;8(1):4619. doi: 10.1038/s41598-018-22620-2.

6.

HCV Genotype 6a Escape From and Resistance to Velpatasvir, Pibrentasvir, and Sofosbuvir in Robust Infectious Cell Culture Models.

Pham LV, Ramirez S, Gottwein JM, Fahnøe U, Li YP, Pedersen J, Bukh J.

Gastroenterology. 2018 Jun;154(8):2194-2208.e12. doi: 10.1053/j.gastro.2018.02.017. Epub 2018 Feb 15.

PMID:
29454794
7.

Efficacy of NS5A Inhibitors Against Hepatitis C Virus Genotypes 1-7 and Escape Variants.

Gottwein JM, Pham LV, Mikkelsen LS, Ghanem L, Ramirez S, Scheel TKH, Carlsen THR, Bukh J.

Gastroenterology. 2018 Apr;154(5):1435-1448. doi: 10.1053/j.gastro.2017.12.015. Epub 2017 Dec 22.

PMID:
29274866
8.

Efficient Hepatitis C Virus Genotype 1b Core-NS5A Recombinants Permit Efficacy Testing of Protease and NS5A Inhibitors.

Pham LV, Ramirez S, Carlsen THR, Li YP, Gottwein JM, Bukh J.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e00037-17. doi: 10.1128/AAC.00037-17. Print 2017 Jun.

9.

Robust HCV Genotype 3a Infectious Cell Culture System Permits Identification of Escape Variants With Resistance to Sofosbuvir.

Ramirez S, Mikkelsen LS, Gottwein JM, Bukh J.

Gastroenterology. 2016 Nov;151(5):973-985.e2. doi: 10.1053/j.gastro.2016.07.013. Epub 2016 Jul 22.

PMID:
27453546
10.

Hepatitis C Virus Genotype 1 to 6 Protease Inhibitor Escape Variants: In Vitro Selection, Fitness, and Resistance Patterns in the Context of the Infectious Viral Life Cycle.

Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM.

Antimicrob Agents Chemother. 2016 May 23;60(6):3563-78. doi: 10.1128/AAC.02929-15. Print 2016 Jun.

11.

Substitutions at NS3 Residue 155, 156, or 168 of Hepatitis C Virus Genotypes 2 to 6 Induce Complex Patterns of Protease Inhibitor Resistance.

Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM.

Antimicrob Agents Chemother. 2015 Dec;59(12):7426-36. doi: 10.1128/AAC.01953-15. Epub 2015 Sep 21.

12.

Adaptive Mutations Enhance Assembly and Cell-to-Cell Transmission of a High-Titer Hepatitis C Virus Genotype 5a Core-NS2 JFH1-Based Recombinant.

Mathiesen CK, Prentoe J, Meredith LW, Jensen TB, Krarup H, McKeating JA, Gottwein JM, Bukh J.

J Virol. 2015 Aug;89(15):7758-75. doi: 10.1128/JVI.00039-15. Epub 2015 May 20.

13.

Production and characterization of high-titer serum-free cell culture grown hepatitis C virus particles of genotype 1-6.

Mathiesen CK, Jensen TB, Prentoe J, Krarup H, Nicosia A, Law M, Bukh J, Gottwein JM.

Virology. 2014 Jun;458-459:190-208. doi: 10.1016/j.virol.2014.03.021. Epub 2014 May 24.

14.

Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.

Li YP, Ramirez S, Humes D, Jensen SB, Gottwein JM, Bukh J.

Gastroenterology. 2014 Mar;146(3):812-821.e4. doi: 10.1053/j.gastro.2013.11.009. Epub 2013 Nov 18.

PMID:
24262279
15.

Hypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virus.

Prentoe J, Serre SB, Ramirez S, Nicosia A, Gottwein JM, Bukh J.

J Virol. 2014 Feb;88(3):1725-39. doi: 10.1128/JVI.02017-13. Epub 2013 Nov 20.

16.

Adapted J6/JFH1-based Hepatitis C virus recombinants with genotype-specific NS4A show similar efficacies against lead protease inhibitors, alpha interferon, and a putative NS4A inhibitor.

Gottwein JM, Jensen SB, Serre SB, Ghanem L, Scheel TK, Jensen TB, Krarup H, Uzcategui N, Mikkelsen LS, Bukh J.

Antimicrob Agents Chemother. 2013 Dec;57(12):6034-49. doi: 10.1128/AAC.01176-13. Epub 2013 Sep 23.

17.

Identification of alpha interferon-induced envelope mutations of hepatitis C virus in vitro associated with increased viral fitness and interferon resistance.

Serre SB, Krarup HB, Bukh J, Gottwein JM.

J Virol. 2013 Dec;87(23):12776-93. doi: 10.1128/JVI.00901-13. Epub 2013 Sep 18.

18.

Highly efficient infectious cell culture of three hepatitis C virus genotype 2b strains and sensitivity to lead protease, nonstructural protein 5A, and polymerase inhibitors.

Ramirez S, Li YP, Jensen SB, Pedersen J, Gottwein JM, Bukh J.

Hepatology. 2014 Feb;59(2):395-407. doi: 10.1002/hep.26660. Epub 2013 Dec 13.

PMID:
23913364
19.

Analysis of hepatitis C virus core/NS5A protein co-localization using novel cell culture systems expressing core-NS2 and NS5A of genotypes 1-7.

Galli A, Scheel TK, Prentoe JC, Mikkelsen LS, Gottwein JM, Bukh J.

J Gen Virol. 2013 Oct;94(Pt 10):2221-35. doi: 10.1099/vir.0.053868-0. Epub 2013 Aug 1.

PMID:
23907394
20.

Viral hepatitis: Cell-culture-derived HCV--a promising vaccine antigen.

Gottwein JM, Bukh J.

Nat Rev Gastroenterol Hepatol. 2013 Sep;10(9):508-9. doi: 10.1038/nrgastro.2013.136. Epub 2013 Jul 30.

PMID:
23897287
21.

Productive homologous and non-homologous recombination of hepatitis C virus in cell culture.

Scheel TK, Galli A, Li YP, Mikkelsen LS, Gottwein JM, Bukh J.

PLoS Pathog. 2013 Mar;9(3):e1003228. doi: 10.1371/journal.ppat.1003228. Epub 2013 Mar 28.

22.

Combination treatment with hepatitis C virus protease and NS5A inhibitors is effective against recombinant genotype 1a, 2a, and 3a viruses.

Gottwein JM, Jensen SB, Li YP, Ghanem L, Scheel TK, Serre SB, Mikkelsen L, Bukh J.

Antimicrob Agents Chemother. 2013 Mar;57(3):1291-303. doi: 10.1128/AAC.02164-12. Epub 2012 Dec 28.

23.

Highly efficient full-length hepatitis C virus genotype 1 (strain TN) infectious culture system.

Li YP, Ramirez S, Jensen SB, Purcell RH, Gottwein JM, Bukh J.

Proc Natl Acad Sci U S A. 2012 Nov 27;109(48):19757-62. doi: 10.1073/pnas.1218260109. Epub 2012 Nov 14.

24.

Efficient replication of genotype 3a and 4a hepatitis C virus replicons in human hepatoma cells.

Saeed M, Scheel TK, Gottwein JM, Marukian S, Dustin LB, Bukh J, Rice CM.

Antimicrob Agents Chemother. 2012 Oct;56(10):5365-73. doi: 10.1128/AAC.01256-12. Epub 2012 Aug 6.

25.

Analysis of functional differences between hepatitis C virus NS5A of genotypes 1-7 in infectious cell culture systems.

Scheel TK, Prentoe J, Carlsen TH, Mikkelsen LS, Gottwein JM, Bukh J.

PLoS Pathog. 2012;8(5):e1002696. doi: 10.1371/journal.ppat.1002696. Epub 2012 May 24.

26.

Robust full-length hepatitis C virus genotype 2a and 2b infectious cultures using mutations identified by a systematic approach applicable to patient strains.

Li YP, Ramirez S, Gottwein JM, Scheel TK, Mikkelsen L, Purcell RH, Bukh J.

Proc Natl Acad Sci U S A. 2012 May 1;109(18):E1101-10. doi: 10.1073/pnas.1203829109. Epub 2012 Mar 30.

27.

Non-genotype-specific role of the hepatitis C virus 5' untranslated region in virus production and in inhibition by interferon.

Li YP, Ramirez S, Gottwein JM, Bukh J.

Virology. 2011 Dec 20;421(2):222-34. doi: 10.1016/j.virol.2011.10.002. Epub 2011 Oct 24.

28.

Vaccine-induced cross-genotype reactive neutralizing antibodies against hepatitis C virus.

Meunier JC, Gottwein JM, Houghton M, Russell RS, Emerson SU, Bukh J, Purcell RH.

J Infect Dis. 2011 Oct 15;204(8):1186-90. doi: 10.1093/infdis/jir511.

29.

Differential efficacy of protease inhibitors against HCV genotypes 2a, 3a, 5a, and 6a NS3/4A protease recombinant viruses.

Gottwein JM, Scheel TK, Jensen TB, Ghanem L, Bukh J.

Gastroenterology. 2011 Sep;141(3):1067-79. doi: 10.1053/j.gastro.2011.06.004. Epub 2011 Jun 12.

PMID:
21699793
30.

Development and application of hepatitis C reporter viruses with genotype 1 to 7 core-nonstructural protein 2 (NS2) expressing fluorescent proteins or luciferase in modified JFH1 NS5A.

Gottwein JM, Jensen TB, Mathiesen CK, Meuleman P, Serre SB, Lademann JB, Ghanem L, Scheel TK, Leroux-Roels G, Bukh J.

J Virol. 2011 Sep;85(17):8913-28. doi: 10.1128/JVI.00049-11. Epub 2011 Jun 22.

31.

MicroRNA-122 antagonism against hepatitis C virus genotypes 1-6 and reduced efficacy by host RNA insertion or mutations in the HCV 5' UTR.

Li YP, Gottwein JM, Scheel TK, Jensen TB, Bukh J.

Proc Natl Acad Sci U S A. 2011 Mar 22;108(12):4991-6. doi: 10.1073/pnas.1016606108. Epub 2011 Mar 7.

32.

Efficient culture adaptation of hepatitis C virus recombinants with genotype-specific core-NS2 by using previously identified mutations.

Scheel TK, Gottwein JM, Carlsen TH, Li YP, Jensen TB, Spengler U, Weis N, Bukh J.

J Virol. 2011 Mar;85(6):2891-906. doi: 10.1128/JVI.01605-10. Epub 2010 Dec 22.

33.

Hypervariable region 1 differentially impacts viability of hepatitis C virus strains of genotypes 1 to 6 and impairs virus neutralization.

Prentoe J, Jensen TB, Meuleman P, Serre SB, Scheel TK, Leroux-Roels G, Gottwein JM, Bukh J.

J Virol. 2011 Mar;85(5):2224-34. doi: 10.1128/JVI.01594-10. Epub 2010 Dec 1.

34.

Recombinant HCV variants with NS5A from genotypes 1-7 have different sensitivities to an NS5A inhibitor but not interferon-α.

Scheel TK, Gottwein JM, Mikkelsen LS, Jensen TB, Bukh J.

Gastroenterology. 2011 Mar;140(3):1032-42. doi: 10.1053/j.gastro.2010.11.036. Epub 2010 Nov 25.

PMID:
21111742
35.

Novel infectious cDNA clones of hepatitis C virus genotype 3a (strain S52) and 4a (strain ED43): genetic analyses and in vivo pathogenesis studies.

Gottwein JM, Scheel TK, Callendret B, Li YP, Eccleston HB, Engle RE, Govindarajan S, Satterfield W, Purcell RH, Walker CM, Bukh J.

J Virol. 2010 May;84(10):5277-93. doi: 10.1128/JVI.02667-09. Epub 2010 Mar 3.

36.

Development and characterization of hepatitis C virus genotype 1-7 cell culture systems: role of CD81 and scavenger receptor class B type I and effect of antiviral drugs.

Gottwein JM, Scheel TK, Jensen TB, Lademann JB, Prentoe JC, Knudsen ML, Hoegh AM, Bukh J.

Hepatology. 2009 Feb;49(2):364-77. doi: 10.1002/hep.22673.

PMID:
19148942
37.

Highly efficient JFH1-based cell-culture system for hepatitis C virus genotype 5a: failure of homologous neutralizing-antibody treatment to control infection.

Jensen TB, Gottwein JM, Scheel TK, Hoegh AM, Eugen-Olsen J, Bukh J.

J Infect Dis. 2008 Dec 15;198(12):1756-65. doi: 10.1086/593021.

PMID:
19032070
38.

Cutting the gordian knot-development and biological relevance of hepatitis C virus cell culture systems.

Gottwein JM, Bukh J.

Adv Virus Res. 2008;71:51-133. doi: 10.1016/S0065-3527(08)00002-X. Review.

PMID:
18585527
39.

Development of JFH1-based cell culture systems for hepatitis C virus genotype 4a and evidence for cross-genotype neutralization.

Scheel TK, Gottwein JM, Jensen TB, Prentoe JC, Hoegh AM, Alter HJ, Eugen-Olsen J, Bukh J.

Proc Natl Acad Sci U S A. 2008 Jan 22;105(3):997-1002. doi: 10.1073/pnas.0711044105. Epub 2008 Jan 14.

40.

Robust hepatitis C genotype 3a cell culture releasing adapted intergenotypic 3a/2a (S52/JFH1) viruses.

Gottwein JM, Scheel TK, Hoegh AM, Lademann JB, Eugen-Olsen J, Lisby G, Bukh J.

Gastroenterology. 2007 Nov;133(5):1614-26. Epub 2007 Aug 3.

PMID:
17983807
41.

Hepatitis C virus host cell interactions uncovered.

Gottwein JM, Bukh J.

Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13215-6. Epub 2007 Aug 7. No abstract available.

42.

Protective efficacy of anti-Helicobacter pylori immunity following systemic immunization of neonatal mice.

Eisenberg JC, Czinn SJ, Garhart CA, Redline RW, Bartholomae WC, Gottwein JM, Nedrud JG, Emancipator SE, Boehm BB, Lehmann PV, Blanchard TG.

Infect Immun. 2003 Apr;71(4):1820-7.

43.

Protective anti-Helicobacter immunity is induced with aluminum hydroxide or complete Freund's adjuvant by systemic immunization.

Gottwein JM, Blanchard TG, Targoni OS, Eisenberg JC, Zagorski BM, Redline RW, Nedrud JG, Tary-Lehmann M, Lehmann PV, Czinn SJ.

J Infect Dis. 2001 Aug 1;184(3):308-14. Epub 2001 Jul 10.

PMID:
11443556

Supplemental Content

Loading ...
Support Center